Evidence map›Paper›PMID 37998775›Full record

ArticleAntibiotics (Basel, Switzerland)2023

BIChromET: A Chromogenic Culture Medium for Detection of Piperacillin/Tazobactam and Cefepime Resistance in

José Manuel Ortiz de la Rosa, Ángel Rodríguez-Villodres, Guillermo Martín-Gutiérrez, Carmen Cintora Mairal, José Luis García Escobar, Lydia Gálvez-Benítez, José Miguel Cisneros, José Antonio Lepe

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

José Manuel Ortiz de la RosaClinical Unit of Infectious Diseases, Microbiology and Parasitology, University Hospital Virgen del Rocío, 41013 Seville, Spain.
Ángel Rodríguez-VillodresClinical Unit of Infectious Diseases, Microbiology and Parasitology, University Hospital Virgen del Rocío, 41013 Seville, Spain.
Guillermo Martín-GutiérrezClinical Unit of Infectious Diseases, Microbiology and Parasitology, University Hospital Virgen del Rocío, 41013 Seville, Spain.
Carmen Cintora MairalClinical Unit of Infectious Diseases, Microbiology and Parasitology, University Hospital Virgen del Rocío, 41013 Seville, Spain.
José Luis García EscobarClinical Unit of Infectious Diseases, Microbiology and Parasitology, University Hospital Virgen del Rocío, 41013 Seville, Spain.
Lydia Gálvez-BenítezClinical Unit of Infectious Diseases, Microbiology and Parasitology, University Hospital Virgen del Rocío, 41013 Seville, Spain.
José Miguel CisnerosClinical Unit of Infectious Diseases, Microbiology and Parasitology, University Hospital Virgen del Rocío, 41013 Seville, Spain.
José Antonio LepeClinical Unit of Infectious Diseases, Microbiology and Parasitology, University Hospital Virgen del Rocío, 41013 Seville, Spain.ORCID 0000-0002-3635-4930
Instituto de Salud Carlos III · ESInstituto de Biomedicina de Sevilla · ESUniversidad Loyola Andalucía · ES

Funding

Instituto de Salud Carlos III CD21/00098Instituto de Salud Carlos III CM22/00196Instituto de Salud Carlos III JR19/00039Instituto de Salud Carlos III JR20/00023Instituto de Salud Carlos III PI20/01829Instituto de Salud Carlos III PI22/01464
6 · The paper itself

Abstract

objectivesThe BIChromET selective medium for detecting piperacillin-tazobactam (TZP) and cefepime (FEP) resistant

methodsThe performance of this medium was first evaluated using a collection of 100

resultsThe BIChromET medium showed excellent sensitivity (TZP (avg. 96.7%); FEP (avg. 92.7%)) and specificity (TZP (avg. 98.9%); FEP (avg. 98%)) in distinguishing the detection limit ranging from 10

conclusionThis medium allows for easy and accurate detection of TZP/FEP-resistant isolates regardless of their resistance mechanisms.

Identifiers

PMID37998775
PMCPMC10668787
OpenAlexW4388020587

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.